JP2010528038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010528038A5 JP2010528038A5 JP2010509526A JP2010509526A JP2010528038A5 JP 2010528038 A5 JP2010528038 A5 JP 2010528038A5 JP 2010509526 A JP2010509526 A JP 2010509526A JP 2010509526 A JP2010509526 A JP 2010509526A JP 2010528038 A5 JP2010528038 A5 JP 2010528038A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- composition according
- disease
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims 6
- 239000003153 chemical reaction reagent Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims 4
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 229940015043 glyoxal Drugs 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims 1
- 239000005695 Ammonium acetate Substances 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 229940043376 ammonium acetate Drugs 0.000 claims 1
- 235000019257 ammonium acetate Nutrition 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93294807P | 2007-05-22 | 2007-05-22 | |
| US60/932,948 | 2007-05-22 | ||
| PCT/US2008/064374 WO2008147815A1 (en) | 2007-05-22 | 2008-05-21 | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010528038A JP2010528038A (ja) | 2010-08-19 |
| JP2010528038A5 true JP2010528038A5 (enExample) | 2011-07-07 |
| JP5457338B2 JP5457338B2 (ja) | 2014-04-02 |
Family
ID=40075474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010509526A Active JP5457338B2 (ja) | 2007-05-22 | 2008-05-21 | ３−（イミダゾリル）−ピラゾロ［３，４−ｂ］ピリジン |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US7629344B2 (enExample) |
| EP (1) | EP2155712B1 (enExample) |
| JP (1) | JP5457338B2 (enExample) |
| KR (1) | KR101534661B1 (enExample) |
| CN (1) | CN101743238B (enExample) |
| AR (2) | AR066701A1 (enExample) |
| AU (1) | AU2008256862B2 (enExample) |
| BR (1) | BRPI0811849A8 (enExample) |
| CA (1) | CA2687625C (enExample) |
| CL (1) | CL2008001493A1 (enExample) |
| CO (1) | CO6241152A2 (enExample) |
| DK (1) | DK2155712T3 (enExample) |
| EA (1) | EA015529B1 (enExample) |
| ES (1) | ES2600477T3 (enExample) |
| HU (1) | HUE032273T2 (enExample) |
| IL (1) | IL202248A (enExample) |
| JO (1) | JO3319B1 (enExample) |
| MA (1) | MA31442B1 (enExample) |
| MX (1) | MX2009012567A (enExample) |
| NZ (1) | NZ581405A (enExample) |
| PE (1) | PE20090293A1 (enExample) |
| PL (1) | PL2155712T3 (enExample) |
| PT (1) | PT2155712T (enExample) |
| TW (1) | TWI418353B (enExample) |
| UA (1) | UA99619C2 (enExample) |
| WO (1) | WO2008147815A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7777035B2 (en) * | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| PT2081921E (pt) | 2006-07-10 | 2010-12-10 | Paion Uk Ltd | Sais de benzodiazepina de acção curta e suas formas polimórficas |
| NZ581405A (en) * | 2007-05-22 | 2011-06-30 | Chemocentryx Inc | 3-(Imidazolyl)-pyrazolo[3,4-b]pyridines and their use in treating CCR1-mediated disorders |
| BRPI0918517B8 (pt) | 2008-09-11 | 2021-05-25 | Chemocentryx Inc | composto, composição farmacêutica, e, uso de um composto |
| EP2305647A1 (en) | 2009-09-18 | 2011-04-06 | PAION UK Limited | Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process |
| EP2450039A1 (en) | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
| SG11201501479QA (en) * | 2012-08-27 | 2015-04-29 | Chemocentryx Inc | Antagonists of chemokine receptors |
| SG11201504410PA (en) * | 2012-12-07 | 2015-07-30 | Chemocentryx Inc | Diazole lactams |
| AR094963A1 (es) | 2013-03-04 | 2015-09-09 | Ono Pharmaceutical Co | Reacción de oxidación excelente en el índice de conversión |
| US20170195506A1 (en) * | 2015-12-30 | 2017-07-06 | Kabushiki Kaisha Toshiba | Image forming apparatus forming location free print system and print job retrieval method by the same |
| AU2017246460B2 (en) | 2016-04-07 | 2021-04-22 | Chemocentryx, Inc. | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors |
| KR102890201B1 (ko) | 2019-07-10 | 2025-11-24 | 케모센트릭스, 인크. | Pd-l1 억제제로서의 인단 |
| PH12022550877A1 (en) | 2019-10-16 | 2023-03-27 | Chemocentryx Inc | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
| JP7736678B2 (ja) | 2019-10-16 | 2025-09-09 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US715746A (en) * | 1902-02-25 | 1902-12-16 | Nat Tube Co | Apparatus for handling tube-plates. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| IE47467B1 (en) * | 1977-10-26 | 1984-03-21 | Wellcome Found | Imidazoline derivatives and their salts |
| AU518569B2 (en) * | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| US4927942A (en) * | 1988-12-15 | 1990-05-22 | Texaco Chemical Co. | Method for the preparation of imidazoles |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| DE69110787T2 (de) | 1990-02-28 | 1996-04-04 | Medtronic, Inc., Minneapolis, Minn. | Intraluminale prothese mit wirkstoffeluierung. |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| US5833651A (en) | 1996-11-08 | 1998-11-10 | Medtronic, Inc. | Therapeutic intraluminal stents |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US20050256130A1 (en) * | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| US7842693B2 (en) * | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
| US7589199B2 (en) * | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
| KR101255356B1 (ko) * | 2002-06-12 | 2013-04-17 | 케모센트릭스, 인크. | 염증 및 면역 질병의 치료를 위한 ｃｃｒ１ 길항물질로서사용하기 위한 1-아릴-4-치환된 피페라진 유도체 |
| US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
| US7435831B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| US7435830B2 (en) * | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| US7777035B2 (en) * | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| EA017278B9 (ru) * | 2005-06-22 | 2013-01-30 | Кемосентрикс, Инк. | Соединения азаиндазола и способы применения |
| KR200434921Y1 (ko) * | 2006-07-10 | 2007-01-02 | 서용석 | 야외용 간이 화장실 |
| NZ581405A (en) * | 2007-05-22 | 2011-06-30 | Chemocentryx Inc | 3-(Imidazolyl)-pyrazolo[3,4-b]pyridines and their use in treating CCR1-mediated disorders |
-
2008
- 2008-05-21 NZ NZ581405A patent/NZ581405A/en unknown
- 2008-05-21 MX MX2009012567A patent/MX2009012567A/es active IP Right Grant
- 2008-05-21 AU AU2008256862A patent/AU2008256862B2/en active Active
- 2008-05-21 BR BRPI0811849A patent/BRPI0811849A8/pt not_active IP Right Cessation
- 2008-05-21 US US12/124,894 patent/US7629344B2/en active Active
- 2008-05-21 EA EA200901572A patent/EA015529B1/ru not_active IP Right Cessation
- 2008-05-21 PT PT87560546T patent/PT2155712T/pt unknown
- 2008-05-21 EP EP08756054.6A patent/EP2155712B1/en active Active
- 2008-05-21 ES ES08756054.6T patent/ES2600477T3/es active Active
- 2008-05-21 WO PCT/US2008/064374 patent/WO2008147815A1/en not_active Ceased
- 2008-05-21 CA CA2687625A patent/CA2687625C/en active Active
- 2008-05-21 JP JP2010509526A patent/JP5457338B2/ja active Active
- 2008-05-21 KR KR1020097026765A patent/KR101534661B1/ko active Active
- 2008-05-21 UA UAA200913250A patent/UA99619C2/ru unknown
- 2008-05-21 DK DK08756054.6T patent/DK2155712T3/en active
- 2008-05-21 PL PL08756054T patent/PL2155712T3/pl unknown
- 2008-05-21 CN CN200880024760.9A patent/CN101743238B/zh active Active
- 2008-05-21 HU HUE08756054A patent/HUE032273T2/en unknown
- 2008-05-22 PE PE2008000878A patent/PE20090293A1/es not_active Application Discontinuation
- 2008-05-22 TW TW097118925A patent/TWI418353B/zh active
- 2008-05-22 AR ARP080102179A patent/AR066701A1/es not_active Application Discontinuation
- 2008-05-22 CL CL200801493A patent/CL2008001493A1/es unknown
- 2008-05-22 JO JOP/2008/0231A patent/JO3319B1/ar active
-
2009
- 2009-11-12 US US12/617,620 patent/US7960388B2/en active Active
- 2009-11-19 IL IL202248A patent/IL202248A/en active IP Right Grant
- 2009-11-20 CO CO09132269A patent/CO6241152A2/es active IP Right Grant
- 2009-12-14 MA MA32416A patent/MA31442B1/fr unknown
-
2011
- 2011-05-09 US US13/103,993 patent/US8481545B2/en active Active
-
2013
- 2013-01-04 US US13/734,479 patent/US20130184289A1/en not_active Abandoned
-
2017
- 2017-11-06 AR ARP170103074A patent/AR110128A2/es unknown